NCT03213301View on ClinicalTrials.gov

Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 28, 2017

Primary Completion Date

June 11, 2021

Study Completion Date

June 11, 2021

Conditions
Malignant Pleural Mesothelioma, Advanced
Interventions
DRUG

Lurbinectedin

3.2 mg/m2 i.v. every 3 weeks

Trial Locations (8)

3600

Regionalspital Thun, Thun

5404

Kantonsspital Baden, Baden

6500

IOSI Ospedale Regionale di Bellinzona e Valli, Bellinzona

8401

Kantonsspital St.Gallen, Sankt Gallen

15121

A.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria

20089

Istituto Clinico Humanitas, Rozzano

CH-7000

Kantonsspital Graubuenden, Chur

CH-8401

Kantonsspital Winterthur, Winterthur

All Listed Sponsors
lead

Swiss Cancer Institute

OTHER

NCT03213301 - Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. | Biotech Hunter | Biotech Hunter